Menu
Search
|

Menu

Close
X

Natera Inc NTRA.OQ (NASDAQ Stock Exchange Global Select Market)

32.76 USD
+0.24 (+0.74%)
As of Sep 13
Previous Close 32.52
Open 33.07
Volume 219,178
3m Avg Volume 238,709
Today’s High 33.07
Today’s Low 32.25
52 Week High 33.55
52 Week Low 11.09
Shares Outstanding (mil) 69.60
Market Capitalization (mil) 1,898.73
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY19
67
FY18
258
FY17
210
FY16
217
EPS (USD)
FY19
-0.543
FY18
-2.230
FY17
-2.579
FY16
-1.846
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
7.24
7.90
Price to Book (MRQ)
vs sector
346.55
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
2,478.64
17.64
LT Debt to Equity (MRQ)
vs sector
1,472.74
12.61
Return on Investment (TTM)
vs sector
-98.36
12.69
Return on Equity (TTM)
vs sector
-23,310.27
17.13

EXECUTIVE LEADERSHIP

Matthew Rabinowitz
Executive Chairman of the Board, Co-Founder, Since 2019
Salary: $500,000.00
Bonus: $110,511.00
Steven Chapman
President, Chief Executive Officer, Director, Since 2019
Salary: $372,927.00
Bonus: $32,089.00
Jonathan Sheena
Co-Founder, Chief Technology Officer, Director, Since 2007
Salary: $321,000.00
Bonus: --
Michael Brophy
Chief Financial Officer, Since 2017
Salary: $340,000.00
Bonus: $52,515.00
Robert Schueren
Chief Operating Officer, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

201 Industrial Rd Ste 410
SAN CARLOS   CA   94070-2396

Phone: +1650.2499090

Natera, Inc. is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father(s).

SPONSORED STORIES